Uptake of New Treatments in Urology Practice

Author(s):

Chad A. Reichard, MD ,Karim Chamie, MD, MSHS

Experts discuss their expectations regarding the uptake of new treatments in clinical practice for non–muscle-invasive bladder cancer and other relevant conditions.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Standard of Care and Intravesical Chemotherapy in NMIBC

EP: 2.BCG for treatment of NMIBC

EP: 3.Cystectomy in NMIBC

EP: 4.New Intravesical Delivery Systems and TAR-200 in NMIBC

EP: 5.TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP: 6.TAR-200 Clinical Development Program in NMIBC

EP: 7.Other Investigational Drug Delivery Systems in NMIBC

EP: 8.Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP: 9.FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP: 10.Use and Sequencing of Novel Treatments in NMIBC

EP: 11.Communication of Treatment Options for High-Risk NMIBC

EP: 12.Checkpoint Inhibitors for Treatment of NMIBC

EP: 13.Unmet Needs in NMIBC

EP: 14.Operationalizing TAR-200 and Other Delivery Systems in Practice

EP: 15.Patient Communication and Treatment Adherence in NMIBC

Now Viewing

EP: 16.Uptake of New Treatments in Urology Practice

EP: 17.Final Thoughts and Clinical Trials in NMIBC

Video content above is prompted by the following:

What do you anticipate regarding the uptake of new treatments in clinical practices?

Related Videos

An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC

Case 2: A 63-Year-Old Man With Recurrent HSPC

Comorbidities and Adherence: Tailoring mHSPC Treatment

FDA-Approved Options for High-Risk BCG-Unresponsive NMIBC

Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

Treatment or Lack of Treatment of Small Renal Masses

The current treatment landscape of mHSPC

Strengths and Weaknesses of Imaging Modalities in ccRCC

BPH: Strategies for Guiding Patients From Medication to Intervention

Representation of Black men with mHSPC in clinical trials